· Original article
Regions interest income rises 1.6% as loan growth lifts Q3
Regions interest income reached $1.298 billion in Q3 2026, supported by loan growth and asset repricing, while deposits declined from the prior quarter.
FINANCEVELIX / News
Listed companies, earnings, corporate developments and equity markets. Company and asset tags identify the subjects of a story.
Read the original source and publication date in each article.
Results: 1,322 · Page 16 / 111
· Original article
Regions interest income reached $1.298 billion in Q3 2026, supported by loan growth and asset repricing, while deposits declined from the prior quarter.
· Original article
Citizens outlook for Q4 2026 calls for 4%–5% noninterest income growth, modest expense increases and $200 million in planned share repurchases.
· Original article
The narsoplimab review ended in another negative CHMP opinion, while Omeros plans to end compassionate use and pursue reimbursed patient access.
· Original article
Truist earnings show higher adjusted EPS in Q3 2026, but securities losses cut reported profit as the bank reshapes lending and returns capital.
· Original article
Citizens dividend rises to $0.52 per share after Q3 2026 results, while the bank expands buyback capacity to $1.95 billion despite a revenue miss.
· Original article
UBS relocation discussions with the UK government put London in focus as Switzerland pursues tougher capital backing for foreign subsidiaries.
· Original article
CCL Products earnings call covered Q2 FY27 on October 16, 2026, but the available opening remarks contain no financial results or guidance.
· Original article
Intel stock closed October 15 at $95.37, down 25.1% from September 24, as investors awaited earnings and an update on its foundry business.
· Original article
Doman results for the third quarter of 2026 are due November 6 after market hours, followed by a November 9 analyst call with its CEO and CFO.
· Original article
TransUnion’s Branded Call Display received 2026 invention recognition as the company reported more than 7 billion branded-call impressions.
· Original article
Royalty Pharma dividend of $0.235 per Class A share is payable December 10, 2026, with a November 13 record date for the fourth-quarter distribution.
· Original article
PBAM earnings rose from a year earlier in Q3 2026, but higher expenses and credit provisions reduced profit from the previous quarter.
Charts and market data by TradingView. Availability and delays vary by exchange.